AAV Vector Manufacturing to Accelerate Your Gene Therapy Program
With over 15 years of specialized experience, ISO-certified processes, and 8,000+ successfully manufactured batches, we deliver AAV manufacturing services precisely tailored to your discovery and preclinical development needs. Whether you're initiating a discovery program, scaling up production, or navigating capacity constraints, our proven expertise ensures your development stays on track.
For research use only. Not for use in diagnostic procedures.
Our Commitment to Your Success
- Delivering Vector Quality You Can Trust
- Expert manufacturing, built around your specifications
- Committed to your development timelines
- Delivering Flexible Production Capacity
Your Breakthrough, Our Commitment.
Delivering Vector Quality You Can Trust
Quality isn't negotiable in gene therapy development - it ensures study comparability,
translational confidence, and informed decision-making throughout your program. Our track record speaks for itself:
- 15+ years of dedicated AAV manufacturing expertise
- 8,000+ batches manufactured for critical applications, including NHP and pig studies
- ISO-certified facilities with continuously improving quality systems
- Rigorous quality controls ensuring consistency across every production run
Quality isn't negotiable in gene therapy development - it ensures study comparability,
translational confidence, and informed decision-making throughout your program. Our track record speaks for itself:
- 15+ years of dedicated AAV manufacturing expertise
- 8,000+ batches manufactured for critical applications, including NHP and pig studies
- ISO-certified facilities with continuously improving quality systems
- Rigorous quality controls ensuring consistency across every production run
Expert manufacturing, built around your specifications
AAV programs evolve quickly serotypes change, payloads are optimized, and batch requirements shift. We provide the flexibility and technical depth to accommodate those changes and match your precise requirements:
Experience across 100+ AAV serotypes: Natural serotypes and novel engineered capsids
Scalable production capacity: From 30mL research-scale to 10 L batches, enabling rapid library production and efficient large-volume manufacturing through parallel campaigns
Flexible purification methods: Chromatography (affinity, anion-exchange/AEX) and density gradient ultracentrifugation (iodixanol/IDX or cesium chloride/CsCl)
Comprehensive analytical testing: Potency, identity, and purity assays tailored to each development stage – from early discovery to preclinical studies.
AAV programs evolve quickly serotypes change, payloads are optimized, and batch requirements shift. We provide the flexibility and technical depth to accommodate those changes and match your precise requirements:
Experience across 100+ AAV serotypes: Natural serotypes and novel engineered capsids
Scalable production capacity: From 30mL research-scale to 10 L batches, enabling rapid library production and efficient large-volume manufacturing through parallel campaigns
Flexible purification methods: Chromatography (affinity, anion-exchange/AEX) and density gradient ultracentrifugation (iodixanol/IDX or cesium chloride/CsCl)
Comprehensive analytical testing: Potency, identity, and purity assays tailored to each development stage – from early discovery to preclinical studies.
Committed to your development timelines
Gene therapy timelines are rarely linear programs change direction and dependencies shift. Our project management model reduces dependency risk and maintains momentum through these changes, ensuring adherence to your timelines:
Transparent project management: Clear communication at every stage
Proven on-time delivery: Consistent performance across thousands of client projects
Expedited production options: Available when urgent program needs arise
Dedicated support team: Seamless coordination from order to delivery
Gene therapy timelines are rarely linear programs change direction and dependencies shift. Our project management model reduces dependency risk and maintains momentum through these changes, ensuring adherence to your timelines:
Transparent project management: Clear communication at every stage
Proven on-time delivery: Consistent performance across thousands of client projects
Expedited production options: Available when urgent program needs arise
Dedicated support team: Seamless coordination from order to delivery
Delivering Flexible Production Capacity
We adapt to your operating model not the other way around:
Dedicated manufacturing partnership: Full-service production support for programs without in-house capabilities
Seamless scalability: From 30 mL to 10 L as your program advances through development stages
Workflow integration: Complement your established processes without disruption
We adapt to your operating model not the other way around:
Dedicated manufacturing partnership: Full-service production support for programs without in-house capabilities
Seamless scalability: From 30 mL to 10 L as your program advances through development stages
Workflow integration: Complement your established processes without disruption
Featured resources
Let's Advance Your Gene Therapy Program Together
Ready to move forward? Let's discuss your specific AAV manufacturing requirements and how we deliver the consistency, flexibility, and on-time results your program demands.
Contact our team today to explore how our tailored solutions can accelerate your path from discovery to clinical success.
Questions?
We're here to help.
Contact us 
Explore our AAV services
Recombinant AAV vectors
AAV design recommendations:
- AAV vectors are available in various serotypes, each with unique tissue tropism. Our experts can guide you in selecting the optimal serotype for targeting specific tissues (e.g., AAV6 for cardiac tissue).
- Selection of tissue-specific promoters is crucial for targeting gene expression to specific cell types within a tissue. We offer a variety of promoters validated for in vivo use, allowing for precise control over gene expression.
AAV services
Revvity offers a comprehensive suite of services for AAV vector generation, including:
Upstream processes:
Utilizing adherent or suspension HEK293 cells for vector production with either two-plasmid or three-plasmid packaging systems.
Downstream processes:
Flexible purification options:
- Step Purification: Iodixanol gradient ultracentrifugation.
- Step Purification: Affinity chromatography followed by iodixanol gradient ultracentrifugation for higher purity, ideal for late-stage preclinical applications.
Quality Control overview
Our Quality Control (QC) packages include various assays to assess the integrity and purity of AAV vectors, such as genome titration (qPCR/ddPCR), capsid titration (ELISA), and purity checks (SDS PAGE). Additional assays, such as sterility and mycoplasma tests, are available upon request.
